Syros Pharmaceuticals, Inc. · OTC:SYRS
Syros Pharmaceuticals — Investor Presentation (May 2023)
25 slides from Syros Pharmaceuticals's investor presentation, May 25, 2023
Slide 1: Advancing Novel Treatments for Hematologic Malignancies
Exhibit 99.1 Advancing Novel Treatments for Hematologic Malignancies May 2023
Slide 2: Forward-looking statements
Forward-looking statements This presentation contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended) concerning Syros and other matters, such as Syros’ clinical dev
Slide 3: Advancing new standards of care for frontline treatment of hematologic malignancies
Advancing new standards of care for the frontline treatment of hematologic malignancies TARGETED HEMATOLOGY PORTFOLIO Late-stage clinical trials in multiple hematology indications with the potential to set new standards of care, supported by a growing body of data 3 clinical MULTIPLE NEAR-TERM CATAL
Slide 4: Advancing our hematology focused late-stage clinical pipeline
Advancing our hematology focused late-stage clinical pipeline Commercial Program Indication Early Clinical Mid-clinical Pivotal Rights Newly diagnosed SELECT-MDS-1 Trial HR-MDS (w/aza) Tamibarotene (oral RARα agonist) Americas, Europe, Newly diagnosed Australia and Israel SELECT-AML-1 Trial unfit AM
Slide 5: Multiple value-driving milestones
Multiple value-driving milestones Last patient enrolled for the pivotal CR data from 4Q 23 SELECT-MDS-1 Phase 3 trial Tamibarotene in HR-MDS 3Q 24 Pivotal data from SELECT-MDS-1 Phase 3 trial Initiation of randomized SELECT-AML-1 trial 1Q 23 Tamibarotene Initial data from randomized SELECT-AML-1 tri
Slide 6: Tamibarotene
Tamibarotene Opportunity to establish new SOC in MDS and AML patients with RARA overexpression
Slide 7: Tamibarotene: Compelling profile that addresses large targeted populations
Tamibarotene: Compelling profile that addresses large targeted populations 1 Tamibarotene is a selective and potent RARα agonist Competitive differentiation of tamibarotene with tamibarotene 1 Biologically targeted ✓ Oral ✓ High complete response ✓ 5,6 rates of patients with HR-MDS are of patients w
Slide 8: Significant unmet need in newly diagnosed HR-MDS
Significant unmet need in newly diagnosed HR-MDS • Myelodysplastic syndrome (MDS) is a bone marrow disorder • Higher-Risk MDS (HR-MDS) and acute myeloid leukemia (AML) are on a disease continuum; largely 1,2,3 distinguished by % blasts in marrow Precursor States MDS HR-MDS AML ~21,000 Newly Diagnose
Slide 9: Significant unmet need in newly diagnosed unfit AML
Significant unmet need in newly diagnosed unfit AML Acute myeloid leukemia (AML) is a cancer of the blood forming cells in the bone marrow 1 • ~50% of the patients are not eligible for intensive treatment and are considered “unfit” Precursor States AML MDS HR-MDS ~25,000 Newly Diagnosed Unfit AML Ne
Slide 10: Encouraging, consistent data from multiple trials support clinical development strategy
Encouraging, consistent data from multiple trials support clinical development strategy Growing body of clinical evidence for tamibarotene in MDS and AML 2022 patients with RARA overexpression 2020 SELECT-AML-1 safety lead-in evaluating 3 tami/ven/aza in ND unfit AML patients 2017 4/5 patients with
Slide 11: Tamibarotene has a well-characterized and well-tolerated safety profile
Tamibarotene has a well-characterized and well-tolerated safety profile Safety profile supports use of tamibarotene in combinations with azacitidine in MDS and with venetoclax/azacitidine in AML Single agent in AML and MDS Over 1,000 APL patients treated with 4 Triplet (tami/ven/aza) in AML patients
Slide 12: Ongoing SELECT-MDS-1 Phase 3 trial in newly diagnosed HR-MDS
Ongoing SELECT-MDS-1 Phase 3 trial in newly diagnosed HR-MDS patients with RARA overexpression Tamibarotene + azacitidine Primary endpoint Key secondary endpoint CR rate Overall Survival (OS) randomization SELECT-MDS-1 trial (2:1) (190 patients) (~550 patients) Placebo + azacitidine • Robustly desig
Slide 13: Ongoing SELECT-AML-1 Phase 2 trial of triplet regimen in unfit AML
Ongoing SELECT-AML-1 Phase 2 trial of triplet regimen (tami/ven/aza) in ND unfit AML patients with RARA overexpression Tamibarotene + venetoclax Randomized + azacitidine Safety lead-in randomization Primary endpoint portion of trial* (1:1) completed Composite CR rate ~80 patients Venetoclax + azacit
Slide 14: SY-2101
SY-2101 Highly synergistic with our hematology portfolio
Slide 15: Significant unmet need in newly diagnosed APL
Significant unmet need in newly diagnosed APL Acute promyelocytic leukemia (APL) is a unique subtype of AML and is defined by a fusion of the RARA and PML genes. Current standard of care Market opportunity for an oral therapy >80% IV oral Cure rates ATO ATRA APL accounts for ~10% of all adult AML ca
Slide 16: SY-2101 has the opportunity to become SOC in frontline APL
SY-2101 has the opportunity to become SOC in frontline APL Novel oral form of arsenic trioxide (ATO) with opportunity to replace standard of care for APL ü patients Orally bioavailable with exposures consistent with IV ATO ü Clear development path to approval in frontline APL with potential to lever
Slide 17: Clear development path to approval in frontline APL
Clear development path to approval in frontline APL with potential to leverage emerging data for a more efficient pivotal study Feedback from the FDA and EMA in the context of original SY-2101 PK data supports a single registration study of approximately 215 patients designed with mCR and EFS as pri
Slide 18: SY-5609
SY-5609 Highly selective and potent oral CDK7 inhibitor
Slide 19: SY-5609: Highly selective and potent oral CDK7 inhibitor
S SY-5609: Highly selective and potent oral CDK7 inhibitor Phase 1 study in pancreatic cancer, breast cancer and select solid tumors demonstrates promising clinical activity ü Well-tolerated safety profile in combination with predominantly low-grade AEs ü Broad potential in multiple difficult-to-tre
Slide 20: Clinical activity in heavily pretreated patients in Phase 1/1b trial
Clinical activity in heavily pretreated patients with manageable, predictable tolerability profiles in Phase 1/1b trial Part 2: Combination safety lead-in evaluating SY-5609 and Part 1: Dose escalation evaluating single agent SY-5609 in patients with gemcitabine and SY-5609, gemcitabine and nab-pacl
Slide 21: Preclinical data support SY-5609 in BRAF-mutant CRC with PDL1 inhibitor
Preclinical data support SY-5609 in BRAF-mutant CRC in combination with PDL1 inhibitor: SY-5609 part of Roche’s Phase 1/1b INTRINSIC trial First clinical investigation of CDK7 inhibitor with an immunotherapy Key Milestones: Robust anti-tumor activity in BRAF-mutant • Roche is actively enrolling pati
Slide 22: Earlier Stage Programs
Earlier Stage Programs SYR2S
Slide 23: Earlier stage programs
Earlier stage programs Commercial Rights Program Indication Drug Discovery IND enabling Clinical stage Metastatic pancreatic Safety Lead-In cancer (w/chemo) SY-5609 (oral CDK7 inhibitor) Colorectal cancer Ph1/1b (w/atezolizumab)* SY-12882 Seeking Cancer (oral CDK12 inhibitor) partnerships Cancer CD
Slide 24: Rapidly advancing toward our vision
Rapidly advancing toward our vision Vision Commercial company with medicines that provide a profound benefit for cancer Now patients Advancing late-stage targeted hematology pipeline Preparing for product launch and commercialization Seeking partnership opportunities for SY-5609 and discovery progra
Slide 25: SYR2:S
SYR2:S
Syros Pharmaceuticals — Investor Presentation (May 2023) on 6ix